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Abstract: A new carrier system for controlled release of immunologic peptides based on double 19 
polysaccharide film-coated microparticles (PCMPs) used with liquid products was developed. The 20 
release behavior of PCMPs was shown dependent on the thicknesses of the outer chitosan film and 21 
the inner resistant starch acetate (RSA) film. The in-vitro release results indicated that, with 22 
optimized polysaccharide coating thickness (RSA: 4–5%; chitosan: 6–7%), the release rate of 23 
Thymopoietin (TP5) was less than 30% before the microparticles reached the colon, and was 50% in 24 
the colon. Besides, the bioavailability of PCMPs was evaluated based on the cell proliferation and 25 
protein expression. Compared with the intraperitoneal injection or oral administration, the 26 
immunodeficient rats that were orally administrated with the yogurt containing TP5-loaded PCMPs 27 
with different storage times possessed a good colon-targeting behavior, higher ratios of CD4/CD8 28 
and IgG expression, indicating the improvement in the TP5 immunologic function. 29 
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1. Introduction 37 
Compared with traditional food, functional food provides significant health benefits by 38 
regulating the physiological activity of the human body in addition to the nutritional and sensory 39 
functions (such as color, smell, and taste) (Boer, Urlings, & Bast, 2016). Given that, bioactive 40 
compounds are considered as the material basis of functional food (Izydorczyk et al., 2017). 41 
However, bioactive compounds such as TP5 can be easily destroyed during food processing (Andrés, 42 
Villanueva, & Tenorio, 2016; Buniowska, Carbonellcapella, Frigola, & Esteve, 2016) and storage 43 
(Gonzálezolivares, Añorvemorga, Castañedaovando, Contreraslópez, & Jaimezordaz, 2014; Grace et 44 
al., 2014), as well as in the human physiological environment (Lu, Zhang, Wang, & Chen, 2011; 45 
Zanjani, Tarzi, Sharifan, & Mohammadi, 2013). For the improved effectiveness and bioavailability 46 
of functional ingredients in food, it is significant to design a delivery system for bioactive 47 
compounds with the enhanced stability of bioactive compounds in both the pre-consumption and the 48 
human physiological environments. 49 
Currently, liquid products systems such as yogurt play a major role in functional food (Tansey 50 
& Worsley, 2014). However, technical difficulties, resulting from the pH variation, the digestion 51 
enzymes, and the long transit time, are involved, which could negatively impact on the effective 52 
storage and the oral delivery of these bioactive compounds to the specific parts of the digestive tract 53 
as desired. To overcome these obstacles, it is important to design new controlled release delivery 54 
system for bioactive compounds that can be used in liquid products. The recent progress on the 55 
research of suitable carrier materials includes bacteria-degradable, pH-sensitive, pressure-sensitive, 56 
and time-dependent polymer coating films for the enhanced stability and bioavailability of bioactive 57 
compounds has provided renewed hope (Lin, Chen, & Luo, 2007; Maroni, Zema, Del Curto, Foppoli, 58 
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& Gazzaniga, 2012). Besides for effective storage, alginate (Champagne, 2006; Kailasapathy, 2006), 59 
oligosaccharide (K. N. Chen, Chen, Liu, Lin, & Chiu, 2005), whey protein (Lambert, Weinbreck, & 60 
Kleerebezem, 2008) and Arabia gum(A. Singh, Adak, Karmakar, & Banerjee, 2014) have been 61 
reported to be used as carrier materials for coating bioactive compounds used in different foods such 62 
as milk and fruit juice. Amylose and cacao oil have also been used as carrier materials in liquid 63 
products like oat beverage (Lahtinen, Ouwehand, Salminen, Forssell, & Myllärinen, 2007). Besides, 64 
suitable materials have been developed for controlled-release delivery systems (Constantin, 65 
Bucatariu, Doroftei, & Fundueanu, 2017; Deodhar, Adams, & Trewyn, 2016; Llopislorente, 66 
Lozanotorres, Bernardos, Martinezmanez, & Sancenón, 2017). Given the enormous interest in recent 67 
years towards maintaining biological activity, growing attention has been focused on many 68 
polysaccharides, such as cellulose, pectin, hyaluronic acid and inulin, in developing controlled 69 
release systems (Akhgari, Farahmand, Afrasiabi, Sadeghi, & Vandamme, 2006; Gurav, Kulkarni, 70 
Khan, & Shinde, 2016; W. He, Du, Cao, Xiang, & Fan, 2008; Ribeiro et al., 2016; Zhou, Wang, Hu, 71 
& Luo, 2016). However, in few studies so far, the development of release systems have addressed the 72 
dual purposes of the controlled release of bioactive compounds and the improvement in the storage 73 
stability of functional food. Thus, the paper reports our new efforts in developing controlled 74 
bioactive compound delivery systems with these double advantages. 75 
Starch and chitosan are two polysaccharides that are biocompatible and biodegradable and have 76 
already been widely used in different foods (Z. He et al., 2017; J. Singh, Kaur, & Mccarthy, 2007). 77 
Starch can be modified easily to overcome its native hydrophilicity and limitations against the acid 78 
and enzymes in the gastrointestinal tract (Bayat et al.; L. Chen, Li, Li, & Guo, 2007; Sharma, Yadav, 79 
& Ritika, 2007). The modified starch may avoid being hydrolyzed in the small intestine but can still 80 
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be degraded by the microorganisms in the colon (Pu, Chen, & Li, 2011). It has been reported by our 81 
group that resistant starch acetate (RSA) can be used as a potential carrier for oral colon-specific 82 
delivery (Bie, Chen, Li, & Li, 2016; L. Chen et al., 2007; Li, Peng, Ling, & Long, 2011; Xiao, Liu, 83 
& Sun, 2011). On the other hand, the dissolution and structure of chitosan are highly responsive to 84 
pH in the upper GI tract (Bayat et al., 2008; Pan et al., 2016) and therefore can also be a promising 85 
carrier material. Moreover, by adjusting the molecular structure and thus the film forming properties 86 
of chitosan, the chitosan film can absorb water to form a gel in a weak-acid environment and 87 
dissolve in a strong-acid environment. Therefore, by adjusting the digestion resistibility of starch and 88 
the pH-responsiveness of chitosan based on molecular design, it is possible to develop a complex 89 
polysaccharide material that can be used to construct a controlled-release delivery system for liquid 90 
products. 91 
In this study, colon-targeted controlled-delivery systems based on double polysaccharide 92 
film-coated microparticles (PCMPs) for yogurt were designed using RSA (the degree of substitution: 93 
1.9), which had digestion resistibility, and chitosan (Mw: 1.5×105 g/mol), which was pH-responsive, 94 
as coating materials. TP5-loaded PCMPs were prepared, in which TP5 was used as a model bioactive 95 
compound. Moreover, the release behavior during yogurt storage and in-vitro simulated GI 96 
transportation were investigated, with the variation in the polysaccharide coating thicknesses. 97 
Furthermore, the in-vivo effectiveness of TP5-loaded PCMPs was evaluated by tissue 98 
immunocytochemistry, and the in-vivo TP5 bioactivity was studied in immune model rats. 99 
 100 
 101 
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 102 
2. Materials and methods 103 
2.1 Chemicals and reagents 104 
RSA with the degree of acetyl substitution (DS) of 1.9 was synthesized from a high-amylose 105 
starch (50% amylose content, from Penford, Australia) using the method as previously described 106 
(Zhang, Chen, Zhao, & Li, 2013). Chitosan (Mw: 1.5×105 g/mol) was purchased from Kayon 107 
Biological Technology Co., Ltd. (Shanghai, China). Lactic acid bacteria powder was supplied by 108 
Chuanxiu Technology Co., Ltd. (Beijing, China). Sterilized pure whole milk was provided by Yili 109 
Industrial Group Limited by Share Ltd. (Inner Mongolia, China). Microcrystalline cellulose (SH-102) 110 
was purchased from Anhui Shanhe Medicinal Accessory Material Co., Ltd. (Huainan, China). TP5 111 
was supplied by GL Biology and Chemistry Co., Ltd. (Shanghai, China). FITC, red blood cell lysis, 112 
FITC anticat CD3, PE anticat CD8a, APC anticat CD4, and anticoagulation tubes were purchased 113 
from BD Bioscience Co., Ltd. (USA). The ELISA Kit for Immunoglobulin G (IgG) was supplied by 114 
Chenglin Biological Technology Co., Ltd. (Beijing, China) Cyclophosphamide was purchased from 115 
Aladdin Co., Ltd. (Shanghai, China). 116 
2.2 Preparation of RSA films 117 
The RSA films were prepared by a flow-casting method. RSA was suspended in acetone and 118 
stirred for 3 min to make it dissolve completely. An RSA solution was then prepared, with triacetin 119 
as a plasticizer at a content of 25% (w/w) of RSA. The mixture was stirred for another 8 h, before 120 
casting in a polypropylene plate with a diameter of 14 cm. The cast films were dried in an oven at 121 
45 °C for 12 h, which could then be manually detached from the plate. Finally, 1 g of the RSA film 122 
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was added to 100 g of a fresh fermented yogurt, which was mixed evenly and then stored in a 4 °C 123 
refrigerator for different days (1,7,13,19 days) based on the quality guarantee period of yogurt. 124 
2.3 X-ray diffraction(XRD) 125 
Crystalline structure was identified using an X-ray diffractometer (X'Pert Prox, Panalytial, The 126 
Netherlands) operated at 40 kV and 40 mA with Cu-Ka radiation (0.1542 nm). The diffractograms of 127 
the samples were acquired at an angular angle (2θ) range of 4°to 40° with a step size of 0.033° and a 128 
counting time of 4 s for each step. The ratio of the upper area (crystalline portion) to the total 129 
diffraction area (based on a linear baseline) was taken as the relative crystallinity using the software 130 
MDI Jade 6.0. The relative crystallinity of all these samples was calculated using the MDI Jade 131 
software (Nara & Komiya, 1983). 132 
2.4 Dynamic mechanical properties of RSA films 133 
The dynamic mechanical properties of RSA films were investigated by a PerkinElmer Diamond 134 
dynamic mechanical analyzer (DMA) (PerkinElmer, Inc., Waltham, MA, USA) using the tensile 135 
mode. Rectangular specimens with a dimension of 40 (length) × 10 (width) mm were cut from the 136 
central part of the films using a cutting mold. A frequency of 1.0 Hz was used. The storage modulus 137 
(E’), loss modulus (E’’), mechanical loss factor (tan δ) were recorded. The temperature scanning 138 
proceeded from 30 °C up to 90 °C with a rate of 2 °C/min. Triple tests were carried out to each 139 
sample to ensure data reliability.  140 
2.5 Preparation of polysaccharide-coated microparticles (PCMPs). 141 
TP5 was used as a model bioactive compound. TP5-loaded microparticles (containing 142 
microcrystalline cellulose and starch in the ratio of 3:1) were obtained via extrusion-spheronization 143 
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(Pu et al., 2011). During the extrusion-spheronization, the temperature was kept at 5–10 °C to 144 
maintain the activity of TP5. 145 
The microparticle cores loaded with TP5 were then coated with RSA, and then with chitosan, 146 
using a bottom spray fluid bed coater (Mini-XYT; Xinyite Technology Co., Shenzhen, China) until a 147 
certain weight (thickness) of the coated film was achieved, which was representative of the dry 148 
weight gain of the microparticles (Pu et al., 2011). In this way, seven samples of double 149 
polysaccharide film-coated microparticles (PCMPs) were prepared: Type I: RSA 2.65%, chitosan 150 
8.73%; Type II: RSA 4.15%, chitosan 9.56%; Type III: RSA 7.89%, chitosan 8.26%; Type IV: RSA 151 
4.45%, chitosan 1.47%; Type V: RSA 4.45%，chitosan 3.87%; Type VI: RSA 5.14%, chitosan 7.07%; 152 
Type VII: RSA 4.15%, chitosan 0%) The process parameters were: the inlet temperature at 44±1 °C; 153 
temperature of TP5-loaded microparticles at 30±2 °C; spray rate of coating dispersion at 0.7–0.8 154 
mL/min; atomization pressure of 0.15 MPa; and fluidization pressure at 0.15 MPa. PCMPs were 155 
finally dried in an oven at 45 °C for 24 h. 1 g of PCMPs were added into 100 g of a fresh fermented 156 
yogurt, mixed evenly and then stored in a 4°C refrigerator for 1 to 19 days for the establishment of 157 
liquid products delivery systems. 158 
2.6 Release tests during yogurt storage 159 
After stored in the yogurt for different times, PCMPs were taken out and washed with distilled 160 
water. Furthermore, PCMPs were soaked and fully dissolved in a hydrochloric acid solution of pH 161 
1.2, then ground and filtered. The filtrate was diluted with water to 100 mL. The amount of TP5 162 
released from the PCMPs was determined using a UV spectrophotometer at a wavelength of 275 nm.   163 
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2.7 In-vitro release tests 164 
The in-vitro release behavior of PCMPs was studied according to the China Pharmacopoeia 165 
(2015) dissolution method using a dissolution rate test apparatus (J. Chen et al., 2016). 1 g of PCMPs 166 
stored in yogurt for different times was taken out and washed with distilled water twice, then 167 
immersed in the simulated gastric fluid (SGF) for the first 2 h, in the simulated intestinal fluid (SIF) 168 
for another 6 h, and afterward in the simulated colonic fluid (SCF) for an additional 40 h, in 169 
sequence, all at 37±0.5 °C with agitation using a paddle at a rotation speed of 100 rpm by an 170 
intelligent medicine dissolving instrument (RCZ-8B, Tianjin Tianda Tianfa Technology Co., Ltd., 171 
Tianjin, China) (Pu et al., 2011; Situ, Chen, Wang, & Li, 2014). When the simulated digestive fluid 172 
changed, PCMPs were filtered by filter paper under vacuum, washed with distilled water twice, and 173 
then put into the following simulated digestive fluid. At appropriated time intervals, 5 mL of the 174 
sample was collected from the simulated digestive tract fluid for analysis every one hour, and the 175 
amount of TP5 released from the PCMPs was determined using a UV spectrophotometer at a 176 
wavelength of 275 nm.  177 
2.8 In-vitro fluorescent imaging 178 
Five SPF-grade nude mice (7 to 8 weeks old, all females, Vital River Laboratory Animal 179 
Technology Co., Ltd., Beijing, China) weighing approximately 12−14 g were fasted for 12 h before 180 
the study. The yogurt containing FITC-labeled PCMPs after storage for different times (1 and 13 181 
days) were orally administrated to the stomach via polyethylene tubing under light ether anesthesia. 182 
Meanwhile, three blank groups containing PBS buffer, the yogurt, and FITC-labeled PCMPs were 183 
imaged for comparison. The PCMPs were dosed at 0.2 mg per gram of body weight. At 10, 15, 30, 184 
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45, 60, 90, 120, 150 and 180 min after oral administration, the fluorescence intensity and 185 
transmission of the PCMPs in the nude mice were observed by an small-animal whole-body in-vivo 186 
imaging system (IVIS 200, Xenogen Corp., Alameda, CA, USA) at 445−490 nm of exciting light 187 
and 515−575 nm of emitted light with an exposure time of 5 s. The nude mice were anesthetized by 188 
isoflurane before being photographed. 189 
2.9 TP5 bioactivity 190 
Thirty female rats were randomly divided into six groups for the pharmacodynamics study. The 191 
ratio of CD4/CD8 in the peripheral blood of each rat was determined as an “internal control” before 192 
implantation. The first group of rats were orally administrated with PBS buffer, 2 mL/kg/day, and the 193 
second to the sixth group were immunosuppressed by intraperitoneal injection of cyclophosphamide 194 
(CTX) at a dosage of 35 mg/kg/day. After CTX treatment for 3 days, if the ratio of CD4/CD8 was 195 
beyond the range of 1.5–2.0, the immune deficiency model was considred to be established 196 
successfully. After the establishment of the model of the immune deficiency rats, the second group of 197 
rats was orally administrated with PBS buffer, 2 mL/kg/day, as an immune suppression control group. 198 
In the third to fifth group, each rat was respectively orally administrated with the yogurt without TP5 199 
microparticles, with the TP5 solution (12 mg/kg/day), and with the yogurt containing TP5-loaded 200 
PCMPs after storing 13 days (the dosage of TP5 was 12 mg/kg/day). Meanwhile, in the sixth group, 201 
each rat was given TP5 solution by intraperitoneal injection, 12mg/kg/day. A 200μL aliquot of blood 202 
was collected into a heparinized tube via the caudal vein 2, 5, 8, 12 and 16 days after implantation 203 
and stored at 4 °C. All the samples were analyzed by flow cytometry within 15 min. 204 
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2.10 Flow cytometric analysis of peripheral blood 205 
The lymphocyte populations in the peripheral blood were analyzed by dual-color flow 206 
cytometry. An antibody solution (1 mL) containing 1% serum was transferred to a new centrifuge 207 
tube coated with aluminum foil and then mixed with anti-rat CD4 (25 μL) and anti-rat CD8a (25 μL). 208 
Blood samples (200 μL) were washed with PBS by centrifugation at 1500 rpm for 10 min and then 209 
mixed with the antibody solution (22 μL). After incubation in the dark at room temperature for 30 210 
min, red blood cell lysis buffer (200 μL) was added to the blood sample, incubated in the dark at 211 
room temperature for 10 min, and washed twice with PBS by centrifugation at 1500rpm for 10 min. 212 
Data was analyzed by the CELL Quest software and represented as dual-parameter density plots. 213 
2.11 Enzyme-linked immunosorbent assay (ELISA) analysis of serum antibodies 214 
The concentrations of serum antigen-specific IgG in individual animals were analyzed by 215 
ELISA, according to the manufacturer’s instructions (Bethyl, USA). Individual serum samples at 216 
1:1–1:5 dilutions were tested in triplicate and incubated at 37 °C for 30 min. Subsequently, the bound 217 
antibodies were incubated with horseradish peroxidase (HRP)-conjugated goat anti-rat IgG (1:100) 218 
(Bethyl, USA) at 37 °C for 30min. After washing, the bound HRP-conjugated secondary antibodies 219 
were detected with a tetramethylbenzidine substrate. The reaction was stopped by adding 50 μL/well 220 
of 1 M H2SO4, and the optical density was measured at 450 nm. 221 
2.12 Statistical Analysis 222 
All data were subjected to statistical analysis using the SPSS 16.0 statistical package and were 223 
presented as the mean ± standard deviation (±SD). Differences between groups were estimated by 224 
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analysis of t-test, and P < 0.01 was considered to indicate a statistically significant difference 225 
between two groups. 226 
3. Results and Discussion 227 
3.1 Changes in crystalline structure of RSA film during Yogurt storage 228 
Figure 1a shows the wide-angle XRD spectra of the native RSA film and four samples with the 229 
RSA film in the yogurt after storage for different times (1, 7, 13, 19 days). It can be seen that the 230 
crystalline structure (related to the V-type diffraction pattern) of the RSA film stored in the yogurt 231 
for different days was the same as the native RSA film. For these 5 samples, the relative crystallinity 232 
values were calculated to be 9.2, 10.6, 11.1, 11.6, and 12.0, respectively. The relative crystallinity 233 
was slightly increased with a longer storage time. This was due to the influence of acid and water 234 
molecules in the liquid products, which promoted the degradation and rearrangement of RSA chains. 235 
As a result, the aggregation structure of RSA films was changed, and the ordering of RSA chains was 236 
increased. 237 
3.2 Changes in dynamic thermal-mechanical properties of RSA film during 238 
storage in yogurt 239 
The dynamic thermal-mechanical properties of RSA film as affected by the yogurt were 240 
investigated by DMA, and the results are shown in Fig. 1 b-d. It could be seen that when all samples 241 
were at a low temperature, the E' values were in the range of 4.0×108 – 7.0×108 Pa, indicating that 242 
the films had strong rigidity. With the increased temperature, E' decreased all along, but tan δ firstly 243 
increased and then decreased. The peak of a tan δ curve describes the glass transition temperature (Tg) 244 
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of materials (Zhu, Li, Huang, Chen, & Li, 2013). Here, the storage in the yogurt influenced Tg of the 245 
films significantly, with Tg increased with a longer storage time. 246 
During storage in the yogurt, with the presence of acid and water, the ordering of RSA chains 247 
was improved by rearrangements, leading to the increased crystallinity of the RSA film. Moreover, 248 
the infiltration of water into the film allowed the interactions between RSA chains and water 249 
molecules through hydrogen bonding. These interactions could restrict the movement of starch 250 
molecules and the rigidity of the film, as reflected by increased E' and Tg. The longer the storage 251 
time, the higher were E' and Tg. A longer storage time could also result in embrittlement of the film. 252 
3.3 Effect of coating thicknesses on the release behavior of PCMPs during storage 253 
in yogurt 254 
The PCMPs delivery systems were obtained using TP5 as the model bioactive compound, and 255 
the effect of film coating thicknesses on the TP5 release behavior of PCMPs in the yogurt and in the 256 
simulated human GI tract was investigated. Firstly, PCMPs were coated with three different 257 
thicknesses of RSA but with a similar thickness of chitosan (as shown in Method 2.5 Types I-III).  258 
The release behavior of these three PCMP samples in the yogurt was illustrated in figure 2a. It 259 
can be seen that, for each sample, the release rate of PCMPs was increased with the storage time. 260 
Comparing the cumulative release percentages of TP5 from the three PCMP samples, it was 261 
suggested that under the same storage time and with the same coating thickness of chitosan, the 262 
release rate, which reflected the amount of TP5 in yogurt, was decreased with the increased thickness 263 
of the inner RSA coating. Besides, after storage for 1 and 22 days in the yogurt, PCMP Sample 1 264 
released 16.41% and 29.69% of TP5, respectively. This was mainly due to the loose film of RSA. 265 
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Based on the results of XRD and DMA analysis, the rigidity of RSA film was increased during 266 
storage in the yogurt, which made the RSA film brittle. In this way, TP5 in PCMPs was released 267 
through the gel formed by the outer chitosan layer after storage, which prevented the intrusion by the 268 
surrounding liquid products. Thus, the coating thickness of the inner RSA film was a determinant 269 
factor influencing the release behavior of the bioactive compounds during storage in liquid products. 270 
3.4 Effect of polysaccharide coating thicknesses on the release behavior of 271 
PCMPs in the simulated human GI tract 272 
The release behaviors of three PCMP samples in the simulated human GI tract after storage in 273 
the yogurt for 1, 7, 13, and 19 days was shown in Figure 2b-e. It can be seen that the release rate for 274 
TP5 in every PCMP sample was increased with the increased storage time in the yogurt. Besides, the 275 
release rate for TP5 was decreased with a greater thickness of the RSA coating. It can be proposed 276 
that when PCMPs entered the simulated GI tract environment, the time for the dissolution of chitosan 277 
in gastric acid delayed the release of TP5 in the upper GI tract. After the dissolution of the outer 278 
chitosan layer, the inner RSA film still resisted the erosion by digestive enzymes and gastric acid in 279 
the small intestine, which allowed the targeting delivery of TP5 to the colon, These dual functions 280 
could maximize the biological activity of TP5. 281 
To investigate the effect of chitosan coating thickness on the release rate of the bioactive 282 
compound, PCMPs were coated with three different thickness of chitosan (as shown in Method 2.5 283 
Types IV–VI).The release behaviors of these three PCMP samples in the simulated human GI tract 284 
were shown in Figure 2f-i. The release of TP5 in the colon could be adjusted by the coating 285 
thickness of the outer chitosan layer. When the coating thickness of the inner RSA layer and the outer 286 
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chitosan layer were between 4–5% and 6–7%, respectively, the cumulative TP5 release rates in the 287 
upper GI tract could be controlled to be about 30% and 80% in the colon after storage in the yogurt 288 
for 19 days. This meant that the colon-targeted delivery of TP5 was achieved. 289 
Table 1 shows the release rates of different PCMP samples after storage in the yogurt for 290 
various days. After storage, part of TP5 had already been released at release time 0 h. Moreover, the 291 
release rate of PCMPs in the simulated GI tract was significantly increased. It can be seen that with a 292 
similar coating thickness of RSA, PCMP samples had similar release rate when stored in the yogurt, 293 
while they had different release rate in the GI tract. For RSA-coated microparticles, 39.08% and 294 
50.74% of TP5 were released in the upper GI tract after storage in the yogurt for 1 and 19 days, 295 
respectively, while PCMPs released 16.26–29.78% and 24.08–31.94% after storage for the same 296 
time periods, respectively. These results further suggested that the outer chitosan layer avoided the 297 
release of TP5 before reaching the colon. Furthermore, a certain thickness of chitosan helped restrict 298 
the release of TP5 before the colon, which improved the bioavailability of bioactive compounds. 299 
3.5 Release mechanism of liquid products delivery system with pH responsiveness 300 
and colon-targeted release 301 
Based on the data discussed above, a release mechanism of the delivery systems based on liquid 302 
products with pH responsiveness and colon-targeted release is proposed here as shown in Figure 3. 303 
In the beginning, the bioactive compounds were evenly distributed throughout PCMPs with 304 
RSA as the inner layer and chitosan as the outer layer (Figure 3 I). 305 
When PCMPs were stored in the yogurt, the outer chitosan layer absorbed water. With the 306 
increased storage time, the swelling of the chitosan layer led to the formation of a gel structure 307 
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around the particle (Figure 3 II). The disintegration of the chitosan layer allowed the water and other 308 
substances in the yogurt to be gradually in direct contact with the RSA layer. However, RSA was 309 
capable of resisting water intrusion from the yogurt because of its certain hydrophobicity (Figure 3 310 
III). 311 
During the storage in the yogurt, the ordering of RSA chains was increased through molecular 312 
rearrangements. Moreover, because of the infiltration of water molecules from the surrounding liquid 313 
products for the interaction and hydrogen-bonding formation with starch chains, the movement of 314 
starch chains was restricted, leading to the increased rigidity and embrittlement of the film. If the 315 
RSA layer was not thick enough, with a longer storage time, a small amount of TP5 would be 316 
released from the PCMPs into the surrounding yogurt through the chitosan gel layer. Therefore, the 317 
swelling capacity of the chitosan film, together with the hydrophobicity of the RSA layer, maintained 318 
the stability of the bioactive compound in the liquid products during storage. 319 
After transported from the yogurt to the simulated human GI tract, PCMPs were firstly in 320 
contact with low pH gastric juice. The low pH allowed the outer chitosan gel layer to be dissolved 321 
gradually due to a pair of non-shared electrons on the nitrogen atom of the amino group of chitosan, 322 
which contributed to the combination with a hydrogen ion from the gastric juice (Figure 3 IV). 323 
Meanwhile, gastric juice also began to reach the inner RSA layer. Nevertheless, owing to the high 324 
DS of RSA and thus the resistant starch content, the inner RSA layer was intact, and the release of 325 
bioactive compounds was prevented. After PCMPs had been transported to the small intestine, the 326 
chitosan gel layer was mostly eliminated. The integrity of the RSA layer was mostly kept but could 327 
contain minor damages, which allowed the release of the bioactive compound (Figure 3 V). 328 
  17 
After the PDMCs had been transported to the colon, the colonic microbial fermentation resulted 329 
in holes in the RSA coating layer, which allowed the release of the bioactive compound to the 330 
surrounding colon environment (Figure 3 VI). 331 
In this scheme, RSA had a significant number of acetyl groups, which formed steric hindrance 332 
and resist to digestion. Besides, a certain degree of hydrophobicity of RSA was helpful to resist the 333 
degradation by the acid and various digestive enzymes initially, whereas RSA could still be 334 
fermented by colonic microflora. 335 
3.6 In-vivo colonic targeting and bioadhesion of PCMPs 336 
Using in-vivo fluorescent imaging observed by a small-animal whole-body in-vivo imaging 337 
system, the oral colonic targeting capability of FITC-labeled PCMPs was studied. Figure 4 shows 338 
the distribution of PCMPs in different parts of the GI tract of nude mice at different times after oral 339 
administration. Before administration, no fluorescence was shown in the nude mice (Figure 4a). 340 
With the increased transit time after the oral administration of PCMPs (from 10 to 45 min), the 341 
fluorescence spots moved from the stomach to the small intestine and then to the colon. At 45 min 342 
after oral administration, all the fluorescence spots concentrated in the colon, indicating that PCMPs 343 
had reached the colon (Figure 4d−i). As the transit time was prolonged further, the fluorescence 344 
intensity at the colon was gradually increased, and the fluorescence spots were enlarged, which could 345 
be due to the release of FITC from PCMPs. The results here indicated good colonic targeting of 346 
PCMPs for liquid products. 347 
From Figure 4, it was seen that after oral administration, the FITC-labeled PCMPs that were 348 
stored in the yogurt for 1 and 13 days showed some differences in the time and intensity of 349 
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fluorescent spots in the body. At 15 min after oral administration of the FTIC-labeled PCMPs that 350 
were stored in the yogurt for 13 days, the fluorescent spots appeared in the small intestine, and the 351 
intensity of spot increased gradually for the growing time. At 45 min, the PCMPs that were stored in 352 
the yogurt for 13 days had been transported to the upper colon, and the intensity of spots was 353 
brighter than those without storage or with only one-day storage in the yogurt. This result indicated 354 
that the storage time for PCMPs in liquid products had little influence on colon-targeted delivery.  355 
3.7 Bioavailability of thymus peptide five (TP5) 356 
3.7.1 Effect of TP5 on CD4+ and CD8+ cells 357 
TP5 is a natural polypeptide that promotes the growth of thymus(Janway, 1992). However, if 358 
directly injected or orally administered, TP5 could be degraded easily in the animal body, which 359 
limited its function on T-lymphocytes (Amin et al., 2016). As Figure 5a-d shows, the populations of 360 
CD4+ and CD8+ cells in rats that were orally administrated with the yogurt containing TP5-loaded 361 
PCMPs with different storage time for 7 days were higher than those for the other groups. 362 
From Figure 5e-h it can be seen that as the time increased for oral administration, the 363 
proportions of CD4+ or CD8+ cells to the total lymphocytes in immune deficiency rats were 364 
increased gradually. Also, the proportions reached the maxima on the first day after oral 365 
administration. Subsequently, with the end of the oral administration, the proportions of CD4+ and 366 
CD8+ cells to the total lymphocytes were decreased gradually. 367 
    Table 2 presents the ratio of CD4/CD8 in immune model rats after different days of oral 368 
administration or injection of TP5 solution with the same dosage of TP5. The ratio of CD4/CD8 in 369 
the model control group, the TP5 oral administration group, and the TP5 injection group were all less 370 
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than 1.5. In the TP5 PCMPs yogurt group, the ratio of CD4/CD8 was significantly increased with the 371 
increased time (P < 0.01). At Day 8, the ratio reached the maximum of 1.52, but still within the 372 
normal range. When the time was further extended, the ratio was decreased gradually, which was 373 
similar to the model control group. Moreover, there was no significant difference between the model 374 
control group, the TP5 oral administration group, and the TP5 injection group. These results showed 375 
the pH-responsiveness and the colon-targeted controlled-release performance of PCMPs. After stored 376 
in the yogurt and transported into the rat GI tract, PCMPs released TP5 mainly in the colon. Also, 377 
there were plenty of lymphoid tissue in the colon, which could directly absorb and utilize proteins 378 
such as TP5. This mechanism could prevent the adverse effect of the liver on the bioactive 379 
compound, and allowed TP5 to be absorbed in the colon to make it act on the targeted cells, which 380 
improved the immunological activity of the cells. 381 
Figure 6a-b shows the results regarding the effect of the dosage of oral administration of the 382 
TP5-loaded PDMCs received by immune model rats on the CD4/CD8 value. After 7 days of oral 383 
administration, the CD4/CD8 ratio of the TP5 high-dosage group was significantly increased, which 384 
was even close to the normal range, and better than that of the TP5 injection group. Besides, the 385 
CD4/CD8 ratio was slightly higher in the rats that were orally administrated with the TP5-loaded 386 
PCMPs that were stored in the yogurt for 19 days than that with the TP5-loaded PCMPs that were 387 
stored in the yogurt for 7 days. 388 
3.7.2 Effect of TP5 on rat immunoglobulin (IgG) expression 389 
Table 2 also shows the results regarding the effect of PCMPs on the change in the TP5 390 
concentration in immune deficiency model rats. After modeling, the content of IgG in the blood of 391 
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rats in each group was similar (9.50–12.33 mg/mL) without significant difference. Furthermore, with 392 
a prolonged time after oral administration of the yogurt containing PCMPs, the content of IgG in the 393 
blood of rats was increased gradually, and reached the maximum at Day 12. This was because the 394 
TP5 that was released in the colon was absorbed by the body of the rats, which improved the 395 
immunity of T cells and provided the relevant auxiliary stimulation signal and cytokines, thus 396 
promoting the production of antibodies for B cells. Compared with the TP5 PCMPs yogurt group, 397 
the TP5 oral administration group and the TP5 injection group had a lower content of IgG in the 398 
blood, though there was an improvement within their individual groups with time. 399 
Figure 6c-d shows the effect of dosage of oral administration of TP5-loaded PCMCs on the 400 
change in the IgG expression in immune model rats. It could be seen that the IgG expression of 401 
immune model rats with yogurt treatment contained the different dosage of TP5-loaded PCMPs was 402 
higher (18.6−29.7 mmol/L) than those of the normal group, the control group, and TP5 injection 403 
group. As mentioned earlier, B cell activation requires costimulatory signals and cytokines provided 404 
by T cells. Thus, it was reasonable to see that, regardless of the dosage of TP5, TP5 in PCMPs could 405 
be absorbed by rats and then acted on T cells, which led to the recovery of the cellular immune 406 
activity and improved the immunity of rats eventually. 407 
4. Conclusion 408 
This research is focused on the development of a colon-targeted controlled release system based 409 
on PCMPs for liquid products. The results indicated that both the storage stability and the 410 
colon-targeted controlled release performance of the bioactive compound, TP5, could be achieved 411 
with PCMPs with 4–5% and 6–7% of the inner RSA film and the outer chitosan film, respectively. 412 
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The release rate of TP5 was 50% in the colon, which improved the bioavailability of immune peptide. 413 
Thus, this work has provided a new approach for enhancing the bioavailability of functional foods. 414 
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Figure captions 552 
Figure 1. XRD pattern and DMA results of the RSA film in yogurt for different storage times (a: 553 
XRD patterns; b: storage modulus (E'); c: loss modulus (E"); d: loss angle tangent (tan δ)). 554 
Figure 2. a: Release behaviors of PCMPs during storage in yogurt; b-i: Release behaviors of PCMPs 555 
in the GI tract after storage in yogurt for different days (b and f: 1 day; c and g: 7 days; d and h: 13 556 
days; e and i: 19 days). 557 
Figure 3. Release mechanism of PCMPs stored in yogurt (upper) and that of PCMPs after being 558 
transported to the GI tract (lower). 559 
Figure 4. Transition after oral administration of FITC-labeled PCMPs in the GI tract of nude mice at 560 
different time intervals (from left to right are: the normal group, the control group, the TP5 oral 561 
administration group, the TP5 PCMPs yogurt stored 1 day group, and the TP5 PCMPs yogurt stored 562 
in 13 days group, respectively). 563 
Figure 5. a-d: Flow cytometry graph of rats in different groups after 7 days of administration (a: 564 
control group; b: TP5 oral administration group; c: TP5 injection group; and d: TP5 PCMPs yogurt 565 
group); e-h: Flow cytometry graph of immune model rats at different days after administration with 566 
the yogurt containing TP5-loaded PCMPs (e: 0 day; f: 2 days; g: 8 days; and h: 16 days). 567 
Figure 6. a-b: CD4/CD8 ratios of rats after continuous administration of TP5-loaded PCMPs with 568 
different TP5 dosages for 7 days, with TP5-loaded PCMPs stored in yogurt for 1 day (a) and 19 days 569 
(b). And c-d: IgG concentrations in rats after continuous administration of TP5-loaded PCMPs with 570 
different TP5 dosages for 7 days, with TP5 PCMPs stored in yogurt for 1 day (c) and 19 days (d). 571 
(Low dosage group: 4 mg/kg/d oral administration; medium dosage group: 8 mg/kg/d oral 572 
administration; high dosage group: 12 mg/kg/d oral administration).573 
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Table 1 Release behaviors of RSA film-coated microparticles and PCMPs (mean±SD) 
Release time 0 h 2 h 8 h 24 h 48 h 
Stored for 1 day 
RSA 4.15% 1.50±2.13 22.78±4.65 39.08±4.32 67.43±2.54 91.54±0.29 
RSA 4.15% + chitosan 9.56% 6.52±0.04 7.22±0.03 16.26±6.29 18.06±6.11 24.92±5.16 
RSA 5.14% + chitosan 7.07% 2.09±2.40 16.94±2.13 29.78±1.01 52.82±3.45 72.90±3.15 
Stored for 7 days 
RSA 4.15% 5.73±3.44 22.85±0.35 39.80±0.23 64.56±2.40 86.98±4.96 
RSA 4.15% + chitosan 9.56% 11.10±0.01 17.43±0.13 26.23±0.65 34.44±0.05 49.13±0.26 
RSA 5.14% + chitosan 7.07% 3.06±0.40 17.41±0.13 30.14±1.01 64.90±2.45 78.47±3.15 
Stored for 13 days 
RSA 4.15% 16.39±2.24 36.97±0.24 54.32±0.77 80.14±2.16 100.00±0.00 
RSA 4.15% + chitosan 9.56% 10.58±0.01 15.19±2.67 25.39±2.38 42.76±1.96 56.42±5.45 
RSA 5.14% + chitosan 7.07% 10.66±4.72 18.43±2.93 30.91±4.75 68.82±10.47 82.11±4.29 
Stored for 19 days 
RSA 4.15% 15.48±5.90 34.22±0.63 50.74±0.25 75.50±0.44 96.12±5.49 
RSA 4.15% + chitosan 9.56% 16.80±0.01 17.43±0.13 24.08±1.79 39.71±1.04 56.85±1.90 
RSA 5.14% + chitosan 7.07% 13.99±2.36 18.47±0.39 31.94±0.42 69.21±0.12 80.23±0.77 
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Table 2 The ratio of CD4/CD8 and IgG concentrations of rats in different days after administration 
Time Normal group Control group TP5 oral administration group TP5 injection group TP5 PCMPs yogurt group 
 CD4/CD8 IgG CD4/CD8 IgG CD4/CD8 IgG CD4/CD8 IgG CD4/CD8 IgG 
0d 1.60±0.06Aa 9.82±1.42Ab 1.09±0.25Ba 12.00±0.98Ab 0.90±0.09Ba 12.33±2.32Ac 1.06±0.25Ba 11.81±2.39Ab 0.90±0.17Bb 9.50±1.07Ac 
2d 1.53±0.14Aa 11.92±2.77Aab 1.18±0.13ABa 11.90±0.25Ab 0.96±0.11Ba 12.39±1.60Ac 1.19±0.22Aba 12.21±0.60Ab 1.19±0.23ABa 12.15±2.14Ab 
5d 1.61±0.29Aa 14.23±0.70Aa 1.14±0.01ABa 14.72±0.51Aa 0.98±0.20Ba 14.09±0.81Abc 1.16±0.14Aba 14.76±1.98Aab 1.33±0.29ABab 15.64±1.16Aab 
8d 1.52±0.12Aa 11.22±1.21Bab 1.15±0.11Ba 11.60±1.07Bb 1.11±0.17Ba 16.55±0.94Aa 1.07±0.13Ba 12.95±1.36Bb 1.52±0.16Aa 16.48±1.16Aa 
12d 1.52±0.09Aa 14.43±0.31Ca 0.98±0.12Ba 16.44±0.14Ba 0.99±0.06Ba 16.23±1.19ABab 1.03±0.15Ba 13.38±0.52Ba 1.14±0.04Bab 18.71±0.20Aa 
16d 1.59±0.15Aa 11.26±0.19Aab 0.82±0.21Ba 15.18±1.23Aa 0.66±0.37Ba 10.92±2.26Ac 0.46±0.08Bb 11.98±1.19Ab 0.89±0.04Bb 10.89±1.92Ac 
Values followed by different upper case letters within a column differ significantly (P < 0.01); ccapital letters 
differed from each group at the same time; lower-case letters differed from the time at the same group. 
 
